BioWorld

Sep. 12, 2003

XOMA Plans Public Offering Of 9M Shares Following Panel Nod

Two days after an FDA advisory panel recommended approval of its partnered psoriasis drug Raptiva, XOMA Ltd. disclosed plans for a public offering of 9 million common shares. (BioWorld Today) Read More

Enforcing Rule May Hamstring Companies Seeking SBIR Help

The Lancet Explores Whether Depression, Schizophrenia Both Arise From Similar Genetic Causes

House, Senate Committee Agrees On New Reimbursement Rates

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Feb. 4, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...